Silicon BioDevices Inc.
Lab-on-a-chip for rapid heart attack detection
This article was originally published in Start Up
Silicon BioDevices Inc. is looking to save critical time in heart attack diagnosis as well as billions of dollars in health care costs with the first lab-quality, reader-free, POC device for high-sensitivity measurement of cardiac troponin, a key marker of cardiac damage. Using one drop of whole blood, the company's self-contained blood test provides results within 15 minutes to determine whether or not a patient has experienced a heart attack.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."